Abstract
Stroke is one of the major causes of mortality and disability in adults in industrialized countries. Despite numerous preclinical studies and clinical trials in the field of cerebral ischemia, no pharmacological agent has been validated in the treatment of acute ischemic, except thrombolysis. Cerebral ischemia is not only a neuronal disease but it affects the entire neurovascular unit. The therapeutic strategy in stroke should be more global and combine preventive approaches, acute phase treatment and long-term care to improve recovery and prevent or treat affective and cognitive post-stroke consequences. There is an imperative need to develop disease-modifying drugs, which should be able to induce neuroprotection, to serve as adjuvants for thrombolysis by decreasing the hemorrhagic risk and to limit the long-term post-stroke consequences. This review presents the potential effects of Peroxisome Proliferator-Activated Receptors (PPARs) and of their agonists in stroke. We focus on each PPAR receptor and detail their implication in stroke. PPARs are nuclear receptors, acting as ligand-dependent transcription factors. They are expressed in the neurovascular unit that suggests that PPARs could play a role in stroke. Indeed, it has been shown that they are able to interfere with pathways implicated in the pathophysiology of stroke. They could be an answer to this disease-modifying drug concept, being able to act on the different phases of ischemia.
Keywords: Disease-modifying drugs, PPAR, stroke.
Current Drug Targets
Title:PPARs: A Potential Target for a Disease-Modifying Strategy in Stroke
Volume: 14 Issue: 7
Author(s): Thavarak Ouk, Camille Potey, Sophie Gautier, Michele Bastide, Dominique Deplanque, Bart Staels, Patrick Duriez, Didier Leys and Regis Bordet
Affiliation:
Keywords: Disease-modifying drugs, PPAR, stroke.
Abstract: Stroke is one of the major causes of mortality and disability in adults in industrialized countries. Despite numerous preclinical studies and clinical trials in the field of cerebral ischemia, no pharmacological agent has been validated in the treatment of acute ischemic, except thrombolysis. Cerebral ischemia is not only a neuronal disease but it affects the entire neurovascular unit. The therapeutic strategy in stroke should be more global and combine preventive approaches, acute phase treatment and long-term care to improve recovery and prevent or treat affective and cognitive post-stroke consequences. There is an imperative need to develop disease-modifying drugs, which should be able to induce neuroprotection, to serve as adjuvants for thrombolysis by decreasing the hemorrhagic risk and to limit the long-term post-stroke consequences. This review presents the potential effects of Peroxisome Proliferator-Activated Receptors (PPARs) and of their agonists in stroke. We focus on each PPAR receptor and detail their implication in stroke. PPARs are nuclear receptors, acting as ligand-dependent transcription factors. They are expressed in the neurovascular unit that suggests that PPARs could play a role in stroke. Indeed, it has been shown that they are able to interfere with pathways implicated in the pathophysiology of stroke. They could be an answer to this disease-modifying drug concept, being able to act on the different phases of ischemia.
Export Options
About this article
Cite this article as:
Ouk Thavarak, Potey Camille, Gautier Sophie, Bastide Michele, Deplanque Dominique, Staels Bart, Duriez Patrick, Leys Didier and Bordet Regis, PPARs: A Potential Target for a Disease-Modifying Strategy in Stroke, Current Drug Targets 2013; 14 (7) . https://dx.doi.org/10.2174/1389450111314070005
DOI https://dx.doi.org/10.2174/1389450111314070005 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
p38 MAP Kinase Inhibitors as Potential Therapeutic Drugs for Neural Diseases
Central Nervous System Agents in Medicinal Chemistry Brief Hyperthermia Does not Worsen Outcome after Striatal Hemorrhage in Rats
Current Neurovascular Research The Association of Sleep Disorders, Obesity and Sleep-Related Hypoxia with Cancer
Current Genomics Potential Role of ADAMTS13 in the Progression of Alcoholic Hepatitis
Current Drug Abuse Reviews Risk of Bleeding Related to Antithrombotic Treatment in Cardiovascular Disease
Current Pharmaceutical Design Recent Advances in the Methodology and Application for the Metabolism of Phytochemical Compounds-An Update Covering the Period of 2009-2014
Current Drug Metabolism Hematotoxicity of Co-Administration of Bisphenol A and Acetaminophen in Rats and its Amelioration by Melatonin
Endocrine, Metabolic & Immune Disorders - Drug Targets Anti-Hypertensive Potential and Epigenetics of Angiotensin II type 2 Receptor (AT2R)
Current Hypertension Reviews Postprandial Hypotension - Novel Insights into Pathophysiology and Therapeutic Implications
Current Vascular Pharmacology Highlighting the Role of Cognitive and Brain Reserve in the Substance use Disorder Field
Current Neuropharmacology Myocardial ‘No-Reflow’ Prevention
Current Vascular Pharmacology Design, Optimization and Characterization of Granisetron HCl Loaded Nano-gel for Transdermal Delivery
Pharmaceutical Nanotechnology Treatment of Hypertensive Left Ventricular Hypertrophy
Current Pharmaceutical Design Bacteriophages as Therapeutic and Prophylactic Means: Summary of the Soviet and Post Soviet Experiences
Current Drug Delivery Water Mediated, Eco-friendly Enantioselective Synthesis of Indole Substituted N-heterocyclic Compounds via Friedel-Crafts Alkylation
Letters in Organic Chemistry Neuroprotective Effects of Estrogens: Cross-Talk Between Estrogen and Intracellular Insulin Signalling
Infectious Disorders - Drug Targets Recent Patents Review in Three Dimensional Ultrasound Imaging
Recent Patents on Biomedical Engineering (Discontinued) Metals and Parkinson's Disease: Mechanisms and Biochemical Processes
Current Medicinal Chemistry Role of Platelet Function Testing in Clinical Practice: Current Concepts and Future Perspectives
Current Drug Targets Perinatal Outcome in Pregnant Women with Heart Disease
New Emirates Medical Journal